News out! ScripsAmerica's Specialty Pharmacy Continues Revenue Growth With $4.9 Million in Approved Orders for August
TYSONS CORNER, VA, Sep 03, 2014 (Marketwired via COMTEX) -- ScripsAmerica, Inc. (OTCBB: SCRC) today announced that the Company's managed specialty pharmacy reported $4,867,637 in approved orders during the month of August 2014, marking its fifth consecutive month of sales growth.
Main Avenue Pharmacy's revenue of $4.9 million during August represents a 19% increase over July. ScripsAmerica's managed pharmacy has experienced 884% sales growth over the past five months and now has a run rate of $58 million following August's reported revenue.
CEO of ScripsAmerica Bob Schneiderman commented, "The Company is happy to report that Main Avenue Pharmacy increased its sales revenue by nearly 20% in August over July and continues to show consistent monthly growth. With a run rate nearing $60 million, Scrips' managed specialty pharmacy has become the Company's largest steady source of revenue this year and we believe will continue to build shareholder value to close 2014 and beyond."
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Seal Point Consulting
888-959-7095
Email Contact
SOURCE: ScripsAmerica
(C) 2014 Marketwire L.P. All rights reserved.
-0-
SUBJECT CODE: Manufacturing and Production
ackaging and Containers
Pharmaceuticals and Biotech:Biotech
Professional Servicesurchasing
Pharmaceuticals and Biotech:Equipment and Supplies
Pharmaceuticals and Biotech
rugs
TYSONS CORNER, VA, Sep 03, 2014 (Marketwired via COMTEX) -- ScripsAmerica, Inc. (OTCBB: SCRC) today announced that the Company's managed specialty pharmacy reported $4,867,637 in approved orders during the month of August 2014, marking its fifth consecutive month of sales growth.
Main Avenue Pharmacy's revenue of $4.9 million during August represents a 19% increase over July. ScripsAmerica's managed pharmacy has experienced 884% sales growth over the past five months and now has a run rate of $58 million following August's reported revenue.
CEO of ScripsAmerica Bob Schneiderman commented, "The Company is happy to report that Main Avenue Pharmacy increased its sales revenue by nearly 20% in August over July and continues to show consistent monthly growth. With a run rate nearing $60 million, Scrips' managed specialty pharmacy has become the Company's largest steady source of revenue this year and we believe will continue to build shareholder value to close 2014 and beyond."
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Seal Point Consulting
888-959-7095
Email Contact
SOURCE: ScripsAmerica
(C) 2014 Marketwire L.P. All rights reserved.
-0-
SUBJECT CODE: Manufacturing and Production
ackaging and Containers Pharmaceuticals and Biotech:Biotech
Professional Services
urchasing Pharmaceuticals and Biotech:Equipment and Supplies
Pharmaceuticals and Biotech
rugs 
